

Special Issue

Recent Advances in Nanotechnologies for Cancer Detection and Treatment

Message from the Guest Editor

Cancers are a leading cause of death worldwide, due to metastatic evolution in up to 80% of cases in some cancer sub-types. Cancer cure is possible at localized or locally advanced stages of disease, provided that micrometastatic disease is eradicated by medical treatments. Innovative tools are required to early detect micrometastases, but also to treat resistant cancer cells. In recent years, nanomaterials have been developed for nanomedicine, with increasing complexity for cancer cell detection but also and particularly for therapeutic potential. Nanoparticles with a core that can be excited by an external source (magnetism, light) are promising in targeting cancer cells without damaging surrounding normal tissues. We welcome submissions that will describe the most innovative nanotechnologies for cancer detection and treatment. We are interested in nanotools developed for micrometastasis detection, and those focusing on targeting cancer cells, including cancer stem cells, to reverse chemoresistance, for translational purposes.

Guest Editor

Dr. Guilhem Bousquet

1. INSERM, UMR_S942 MASCOT, F-75006 Paris, France
2. Hospital Avicenne, Université Sorbonne Paris Nord, Villetaneuse, France

Deadline for manuscript submissions

closed (31 March 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/84549

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)